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ABSTRACT
Background Human systemic antibody responses to
commensal microbiota are not well characterised during
health and disease. Of particular interest is the analysis
of their potential modulation caused by chronic HIV-1
infection which is associated with sustained enteropathy
and systemic B cell disturbances reflected by impaired B
cell responses and chronic B cell hyperactivity. The
mechanisms underlying B cell hyperactivation and the
specificities of the resulting hypergammaglobulinaemia
are only poorly understood.
Methods By a technique referred to as live bacterial
FACS (fluorescence-activated cell sorting), the present
study investigated systemic antibody responses to
several gut and skin commensal bacteria as well as
Candida albicans in longitudinal plasma and serum
samples from healthy donors, chronic HIV-1-infected
individuals with or without diarrhoea and patients with
inflammatory bowel disease (IBD).
Results The data show that systemic antibody
responses to the commensal microbiota were
abundantly present in humans and remained remarkably
stable over years. Overall systemic antibody responses
to gut commensal bacteria were not affected during
chronic HIV-1 infection, with titres decreasing when
normalised to elevated plasma immunoglobulin G (IgG)
levels found in patients with HIV. In contrast, increases in
the titres of high affinity antimicrobiota antibodies were
detected in patients with IBD, demonstrating that
conditions with known increased intestinal permeability
and aberrant mutualism can induce changes in antibody
titres observed in these assays.
Conclusion Neither HIV-associated enteropathy nor B
cell dysfunction impact on the high-affinity systemic
antibody responses to gut commensal bacteria.
HIV-associated hypergammaglobulinaemia is therefore
unlikely to be driven by induction of antimicrobiota
antibodies.
INTRODUCTION
The human intestinal tract is inhabited by
commensal bacteria which outnumber the cells of
the human body by a factor of 10. More than 500
different bacterial species are believed to reside in
the human gut, with a majority not amenable to in
vitro culture.1 2 This microflora is known to play
a pivotal role in human health and disease. Unique
adaptations of the intestinal immune system are
crucial to maintain homeostasis with the resident
microbiota.3 Disturbances of this delicate balance
due to external or internal factors are known to
result in enteropathy such as during inflammatory
bowel disease (IBD). They are also reported to be
induced by infectious agents such as HIV-1.4
In fact, HIV-1 infection is tightly linked to the
gastrointestinal tract, which serves as a major site
of viral replication.5 6 Intestinal CD4 T cells are
a preferential target of the virus and are massively
depleted during early infection.7e9 HIVenteropathy
has long been described10 and is associated with
gastrointestinal tract inflammation,11 malabsorp-
tion,10 diarrhoea,12 increased intestinal perme-
ability13 14 and translocation of microbial
products.5 15 16 The underlying mechanisms
contributing to enteropathy may be direct viral
effects4 and/or an indirect consequence of local
immune activation and inflammation.17 18
Significance of this study
What is already known about this subject?
< Enteropathy, B cell dysfunction and hyper-
gammaglobulinaemia are characteristics of
chronic HIV-1 infection.
< How enteropathy and B cell dysfunction impact
on antibody responses to gut commensal
bacteria in HIV-1 infection is unknown.
< The mechanisms underlying hypergammaglobu-
linaemia during HIV-1 infection are not defined.
Antigen-driven stimulation could not be
excluded to date.
What are the new findings?
< HIV enteropathy and B cell dysfunction do not
impact on antibody responses to gut
commensal bacteria even in late-stage HIV-1
infection as normal levels of the gut commensal-
specific antibody response are maintained
throughout the course of infection.
< Severe enteropathy in patients suffering from
inflammatory bowel disease (IBD) is associated
with increased systemic antibody response to
certain gut commensal bacteria.
< In patients with HIV, gut commensal antigens
may be excluded as contributing to hyper-
gammaglobulinaemia in an antigen-dependent
manner.
< Additional figures, tables and
methods are published online
only. To view these files please
visit the journal online (http://
gut.bmj.com).
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Commensal bacteria-specific antibodies play a critical role in
maintaining intestinal balance and fighting systemic dissemi-
nation of bacteria.19 We show here that specific antibody
responses to commensal gut bacteria are abundantly available in
humans on a systemic level.
B cell hyperactivity resulting in hypergammaglobulinaemia
and B cell dysfunction, reflected by poor responsiveness to
vaccination, are hallmarks of HIV-1 pathogenesis.20e24 The
exact mechanisms underlying these B cell disturbances, however,
remain to be elucidated. These B cell disturbances have also been
explicitly characterised in the HIV-infected gut by reports of
intestinal B cell hyperactivity, early destruction of gastrointes-
tinal germinal centres and specific blocking of the intrafollicular
but not extrafollicular immunoglobulin (Ig) switch enzyme
activation-induced deaminase.25e27
In this context of B cell dysfunction and hyper-
gammaglobulinaemia we investigated whether HIVenteropathy,
and therefore increased microbial exposure, produced measurable
increases in the titres of high and low affinity antimicrobial
antibody responses to commensal bacteria. Using a flow cyto-
metric approach referred to as ‘live bacterial FACS’ (fluorescence-
activated cell sorting)28 as well as ELISAwe studied longitudinal,
systemic antibody responses to commensal gut bacteria in chronic
HIV-infected individuals and patients with IBD. In contrast to
patients with IBD who exhibited increased systemic antibody
responses against several gut commensals, antibody responses to
commensal gut bacteria were not altered during chronic HIV-1
infection and were also very well maintained in late stages of the
disease at levels comparable with healthy controls.
MATERIALS AND METHODS
Study individuals
Antiretroviral therapy (ART)-naive HIV study group (n¼79)
All HIV-1-infected patients were enrolled in the Swiss HIV
Cohort Study (SHCS; http://www.shcs.ch). Plasma and serum
samples were obtained from the SHCS sample repository.
Specifically, in this long-term (started in 1988) Swiss multicentre
study, among other symptoms, diarrhoea and AIDS-defining
enteric pathogens are systematically recorded together with
clinical, general, virological and immunological laboratory
parameters.29 Study group characteristics are listed in table 1.
IBD study group (n¼29)
Plasma samples were obtained from the University Hospital
Bern. Patients were subgrouped into mild/active (n¼12) and
active (n¼7) Crohn’s disease (CD) as well as mild (n¼7)
and active/hard (n¼3) ulcerative colitis (UC). Study group
characteristics are listed in table 2.
Healthy donors (n¼29+19)
As it has been described that IgG antibody titres to antigens
derived from certain gut-related bacteria increase with age,30 we
obtained plasma and serum samples for both disease cohorts
from age-matched cohorts of healthy individuals (n¼29 for the
HIV control cohort and n¼19 for the IBD control cohort).
Ethics committee approval and written informed consent from
all study subjects were obtained according to the guidelines of
the University Hospital Zurich and the University Hospital Bern.
Bacteria and Candida albicans
Escherichia coli, Klebsiella pneumoniae and Enterococcus faecalis
were primary isolates from stool samples of healthy individuals.
Staphylococcus epidermidis and Proprionibacterium acnes were
primary human isolates from clinical specimens. Isolation and
typisation were done by the Institute of Medical Microbiology,
University of Zurich. Bacteroides fragilis, Bacteroides thetaiotaomi-
cron and E coli Nissle (Mutaflor) were from the American Type
Culture Collection. B fragilis and B thetaiotaomicron were grown
anaerobically. Legionella pneumophila strain JR32 is also known as
WT Philadelphia-1. Bradyrhizobium japonicum was a gift from Dr
Hauke Hennecke, Institute of Microbiology, ETH Zurich. C
albicans strain SC5314 is a well characterised clinical isolate.31
Live bacterial FACS
Live bacterial FACS was performed similarly to as previously
described.28 Details are described in supplementary figure 1 and
the supplementary materials and methods.
ELISA
Details are described in supplementary figure 1 and the supple-
mentary materials and methods.
Total Ig levels
Total IgA, IgG and IgM levels in plasma or serum samples were
quantified by in-house ELISA. The following antibodies were
used: goat antihuman IgA, IgG and IgM as unlabelled and
horseradish peroxidase (HRP) conjugates (all SouthernBiotech,
Allschwil, Switzerland). Purified human IgA, IgG and IgM (all
Sigma, Buchs, Switzerland) were used for the standard.
Soluble CD14 (sCD14), lipopolysaccharide (LPS) and endotoxin
core IgM antibodies (EndoCabIgM)
Commercially available ELISA kits were used to quantify sCD14
(R&D Systems, Schonenbuch, Switzerland) and EndoCabIgM
(Hycultbiotech, Allschwil, Switzerland) according to the
manufacturer ’s instructions.
Plasma LPSwas quantifiedwith the commercially available LAL
Endochrome kit (CharlesRiver, Allschwil, Switzerland) according
to the manufacturer ’s instructions for low range detection as
previously described.32
Significance of this study
How might it impact on clinical practice in the foreseeable
future?
< In contrast to laboratory mice, the normal human population
displays considerable immunoglobulin G (IgG) priming specific
for their intestinal microbiota, indicating an altered hoste
microbiota relationship in humans and in mice.
< Enteropathy associated with inflammatory bowel disease, but
not enteropathy associated with HIV, results in elevated IgG
titres specific for some members of the intestinal microbiota,
indicating that elevated microbiota-specific IgG is a variable
phenomenon depending on the nature of the enteropathy and
immune status of the individual.
< Patients with HIV maintain normal antibody responses to
persistent antigens and intestinal bacteria despite drastic loss
of CD4 T cells and B cell hyperactivation which may underlie
the limited prevalence of microbiota-derived sepsis in patients
with AIDS.
< The presence of comparable titres of systemic antibodies
specific for intestinal bacteria in healthy individuals and HIV-
infected patients does not support the hypothesis that gut
microbial antigens drive HIV-associated hypergammaglobuli-
naemia and it thus remains a further challenge to identify its
causality.
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Cytomegalovirus (CMV), polio, tetanus toxoid and gp120 IgG
CMV IgG and IgM, polio IgG and tetanus toxoid IgG were
quantified by commercially available ELISA kits (Immunolab,
Kassel, Germany) according to the manufacturer ’s instructions.
Binding titres (IC50) of gp120 IgG were quantified by in-house
ELISA with recombinant gp120 JR-FL as previously described.33
Statistical analysis
A detailed description of the statistical analysis can be found in
the supplementary materials and methods.
RESULTS
Live bacterial FACS allows the study of antibody responses to
commensal bacteria with minimal cross-reactivity
Live bacterial FACS has recently been introduced as a novel flow
cytometric approach to study antibody responses against
bacteria.28 The underlying principle, as illustrated in figure 1A, is
that live bacteria are incubated with diluted plasma or serum
samples and, if the sample contains specific antibodies against
the respective bacteria, they will bind to the bacterial surface.
Binding of these antibodies to the bacteria is then detected by
fluorescence-labelled antihuman Ig antibodies. Fluorescently
stained bacteria are subsequently analysed by flow cytometry.
The intensity of the fluorescent signal relates to the concentra-
tion of specific antibodies in the tested serum or plasma sample
and is calculated in reference to a standard plasma included in
every assay (supplementary figure 1A).
The use of live intact bacteria provides a high specificity and
low cross-reactivity between different bacterial isolates as the
membrane composition of bacteria is isolate specific, and highly
cross-reactive antibodies against conserved intracellular bacterial
proteins such as ribosomal proteins are excluded in this assay.
The specificity of the technique, as previously reported,28 was
validated by staining of bacteria with mouse serum derived from
Table 2 Study cohort characteristics (healthy donors and patients with IBD)
Study group Crohn’s disease Ulcerative colitis Healthy controls
Age at sampling, mean (range) 39 (20e61) 52 (34e70) 40 (26e58)
Sex (male/female) 11/7 8/2 8/16
CDAI score 0e600, mean (range) 114 (0e432) NA NA
Mayo score 0e6, mean (range) NA 4 (0e6) NA
Disease location Ileal disease (n¼5)
Colonic disease (n¼2)
Small and large intestinal disease (n¼11)
Colonic involvement (n¼10) NA
Complications (fissue, fistula,
stenosis, stricture)
Uncomplicated (n¼3)
One or more complications (n¼15)
Uncomplicated (n¼10) NA
Medication Combinations of 5-ASA preparations, methotrexate,
anti-TNF and/or corticosteroids
Combinations of 5-ASA preparations, methotrexate,
mercaptopurines, ciclosporin, anti-TNF and/or corticosteroids
None
ASA, 5-aminosalicylic acid; CDAI, Crohn’s disease activity index; IBD, inflammatory bowel disease; NA, not applicable; TNF, tumour necrosis factor.
Table 1 Study cohort characteristics (healthy donors and ART-naive HIV-infected individuals)
Study group All HIV+ HIV+ (no diarrhoea) HIV+ (with diarrhoea) Healthy controls
n 72 33 39 29
Study period in days, median (range) 342 (55e3652) 2295 (468e3652) 198 (55e491) 216 (187e3287)
No. of samples per patient, median (range) 2 (2e6) 6 (3e6) 2 (2e3) 2 (2e6)
Sex (male/female) 56/16 23/10 33/6 17/12
Age at sampling, median (range) 35.8 (25.2e76) 38.3 (26.4e52.5) 33.2 (25.2e76) 39 (28e56)
CD4 count, median (range) 217 (1.5e760) 208 (110e350) 315 (1.5e760) NA
pVL,* median (range) 53104 (61e5.23105) 63104 (61e5.33105) 1.93104 (1.2e3e1.53105) NA
CDC stage (first sample)
A 60% 77% 49% NA
B 32% 21% 41% NA
C 8% 6% 10% NA
CDC stage (last sample)
A 32% 27% 36% NA
B 40% 42% 38% NA
C 28% 31% 26% NA
HIV subtype
B 97% 97% 97% NA
C 1.50% None 3% NA
Recombinant 1.50% 3% None NA
Risk group
MSM 47% 28% 64% NA
IDU 39% 48% 31% NA
HET 11% 21% 2.50% NA
Bloody 1.40% None 2.50% NA
Unknown 1.40% 3% None NA
ART None None None NA
SMS/TMP 36% 33% 39% NA
*RNA copies/ml.
yBlood transfusion.
ART, highly active antiretroviral therapy; CDC, Centers for Disease Control; HET, heterosexual contact; IDU, intravenous drug use; MSM, men having sex with men; NA, not applicable; SMS/
TMP, sulfamethoxazole/trimethoprim.
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naive mice or from mice previously immunised with the
respective bacteria. Antibody binding could only be detected
against the vaccinating bacterial strain, with no detectable cross-
reactivity towards other bacteria. Serum from naive mice did not
bind detectably to any of the bacterial strains tested (figure 1B).
It has been previously reported for human antibody responses
that cross-reactivity between different bacterial strains such as
bacteroides and enterobacteria is very low.34 Further, to inhibit
potential cross-reactivity due to the presence of natural anti-
bodies which are specific for certain galactose-containing
carbohydrate epitopes, galactose was routinely added to the
assay as has been described before.35
Antibody responses to commensal bacteria are abundantly
detectable in humans and remain remarkably stable over years
IgA, IgG and IgM responses against several human gut (primary
human E coli isolate, E coli Nissle, B fragilis and primary human
E faecalis isolate) and skin commensal bacteria (S epidermidis and
P acnes) as well as C albicans as a human mucosa-associated
commensal fungus were measured in human plasma or serum
samples. In the majority of samples IgA, IgG and IgM responses
were abundantly detectable against these bacteria and C albicans
(figure 2A).
Importantly, to validate the specificity of the technique
further, no antibody responses were detectable against the non-
human-related soil bacterium B japonicum (figure 2B). No or only
very weak responses were detectable against the non-persistent
human pathogen L pneumophila (figure 2B). This is consistent
with previous reports which state <20% of a population to have
antibodies against L pneumophila.36 37
Next, we analysed the stability of these antibody responses
over time. IgA, IgG and IgM responses were compared from >20
healthy and 70 HIV-infected individuals from some of whom
yearly samples were available in a time frame of up to 5e6 years.
Thus, samples from several patients with HIV ranged from the
early phase of infection until late stage and AIDS phase. The
magnitude of responses differed up to 1000-fold between donors
independent of HIV-1 infection, but remained remarkably stable
over the years (figure 3). This might indicate limited changes in
the microbial composition over time, individually different
frequencies of certain commensal bacteria and/or different
individual abilities to mount antibody responses against
a certain bacterial strain.1 38 The stability of responses was seen
despite chronic, untreated progressing HIV-1 infection. In most
patients, longitudinal samples followed the progression to AIDS,
with CD4 counts dropping below 200 cells/mm3. Extensive
statistical analysis confirmed that the commensal bacteria-
specific antibody responses did not significantly change over
time. No significant longitudinal correlation with CD4 counts,
survival or total IgA, IgG and IgM levels was observed. In
addition, the incidence of diarrhoea had no measurable impact
on the antibody responses (data not shown).
Figure 1 (A) Live bacterial FACS
(fluorescence-activated cell sorting).
Illustration of the assay design. (B)
Specificity of the live bacterial FACS
assay. Bacteria were incubated with
naive murine serum (green histograms;
1/60 dilution) or serum from a mouse
which had been immunised with the
respective bacteria (blue histograms, E
coli, 1/60 dilution; L pneumophila and S
typhimurium, 1/450 dilution). Control
bacteria were not incubated with any
serum (black histograms).
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Many bacteria are believed to express antigens which have
blood group reactivity. Due to this ubiquitous AB-reactivity,
individuals with blood group 0 might be suspected to have higher
antibody responses against commensal bacteria. The healthy
donors studied here did not show differences in the magnitude
of responses against gut commensal bacteria between blood
group 0 and the other blood groups (A/B/AB) (supplementary
figure 2).39
Antibody responses to gut commensal bacteria are not affected
by chronic HIV-1 infection and do not contribute to
hypergammaglobulinaemia
After verification that specific antibody responses to commensal
bacteria can be abundantly detected in healthy individuals and
are also remarkably stable over extended time periods in patients
with HIV, live bacterial FACS was now applied to study anti-
body responses in HIV-infected individuals in more detail. To
assess the impact of HIV-associated enteropathy and microbial
translocation5 10 16 in the context of HIV-associated hyper-
gammaglobulinaemia,20 we studied longitudinal plasma or
serum samples of ART-naive chronic HIV-infected individuals
with respect to their antibody titres against a selection of
commensal gut bacteria. As HIV enteropathy and gut perme-
ability were reported to be most markedly increased during
advanced HIV-1 infection,16 we deliberatively chose to study
samples of patients with disease close to or in the AIDS phase
(median CD4 count: 217 cells/mm3 (1.5e760)). Characteristics
of the study cohort are listed in table 1.
Patient samples were grouped into two cohorts: (1) patients
without reported incidence of diarrhoea and (2) patients with
reported incidence of diarrhoea or related gastrointestinal
symptoms. This grouping allowed us to analyse whether the
incidence of diarrhoea further influences the antibody response to
gut commensal bacteria. HIV-infected individuals were compared
with a control study group of 29 HIV-negative age-matched
healthy donors.
First, total IgA, IgG and IgM levels were analysed in plasma or
serum. While total levels of IgA were not significantly different
between HIV-infected and healthy donors, chronic HIV-1
infection was associated with markedly increased levels of total
IgG and IgM in plasma or serum. No differences were observed
between HIV-infected individuals with or without diarrhoea
(figure 4).
We then addressed whether abnormal priming against the
intestinal microbiota was responsible, or contributed to, hyper-
gammaglobulinaemia by quantifying the longitudinal antibody
responses against a selection of gut commensal bacteria
including a primary human E coli isolate (Gram-negative facul-
tative anaerobe bacteria), a primary human E faecalis isolate
(Gram-positive aerobe and anaerobe bacteria), E coli Nissle, B
fragilis (Gram-negative obligate anaerobe bacillus), K pneumoniae
(Gram-negative facultative anaerobe bacteria) and B thetaiotao-
micron (Gram-negative anaerobe bacteria), against S epidermidis
and P acnes (skin commensal bacteria) as well as C albicans
(opportunistic fungus). As mentioned above, extensive statis-
tical analysis confirmed that the commensal bacteria-specific
antibody responses did not significantly change over time. No
significant longitudinal correlation with CD4 counts, survival or,
importantly, total IgG and IgM levels was observed. In addition,
the incidence of diarrhoea had no measurable impact on the
antibody responses (data not shown).
Cross-sectional analysis revealed no differences in the anti-
body responses specific for all tested gut commensal bacteria per
unit plasma volume (ie, the effective antibody concentration per
defined plasma volume and not normalised to the total IgG
level) between HIV-infected individuals and healthy donors,
with the exception of the IgG responses specific for E coli Nissle
and K pneumoniae, for which a slight decrease was observed
when comparing HIV-infected individuals with or without
diarrhoea with healthy controls (figure 5A). No differences
were seen for IgA and IgM responses to the skin commensal
bacteria. However, somewhat unexpectedly and surprisingly IgG
responses per unit volume to S epidermidis and P acnes were
reduced in the HIV-infected study group (figure 5C). None of the
analysed responses differed significantly between HIV-infected
individuals with or without diarrhoea.
Candida-specific IgG responses per unit volume were elevated
in HIV-infected individuals compared with healthy controls
(figure 5A), consistent with previous reports indicating that
C albicans is a well-known AIDS-associated pathogen with
higher colonisation prevalence in patients with AIDS.40 41 All
comparisons mentioned here were tested for significance by
Student t test. We also compared the data by a non-parametric
Wilcoxon rank sum test. Significant differences found by
two-sided t test were confirmed by Wilcoxon rank sum test
(supplementary table 1).
In conclusion, despite increased total IgG and IgM levels,
antibody titres per unit volume of plasma to commensal gut
bacteria were not increased during chronic, progressive HIV-1
infection. This suggests that the drastically increased total IgG
Figure 2 Representative histograms of systemic human immunoglob-
ulin (Ig) responses to bacteria and C albicans measured by live bacterial
FACS analysis. (A) Human IgA, IgG and IgM responses to commensal
bacteria and C albicans and (B) to the non-commensal bacterium L
pneumophila and the soil bacterium B japonicum. Each plot depicts
a histogram (black) of an unstained bacterial sample and several
representative histograms (colours) from bacteria stained with plasma
from different human donors (donors 1e7). The following plasma
dilutions were used: E coli, 1/50; E faecalis, 1/50; B fragilis, 1/5; E coli
Nissle, 1/5; S epidermidis, 1/50; P acnes, 1/50; C albicans, 1/45; L
pneumophila, 1/50; B japonicum, 1/50.
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and IgM antibody levels in HIV-1 infection are not composed
of high affinity antibodies specific for commensal bacteria
and microbial translocation does not contribute to hyper-
gammaglobulinaemia in an antigen-specific manner.
Patients with IBD show elevated systemic antibody titres
against E faecalis, K pneumonia and B thetaiotaomicron
Since chronic HIV-1 infection, even in association with diar-
rhoea, showed no impact on the antibody responses to gut
Figure 4 Total immunoglobulin A (IgA), IgG and IgM levels in healthy donors and HIV-infected individuals with or without diarrhoea. Total levels of
IgA, IgG and IgM were quantified in serum or plasma samples. The median of multiple time points is shown for each donor. p Values (***p<0.001)
were determined by Student t test. Statistical details are listed in supplementary table 1.
Figure 3 Longitudinal antibody responses to commensal bacteria measured by live bacterial FACS analysis. Immunoglobulin A (IgA), IgG and IgM
responses to E coli, E faecalis and S epidermidis were measured in longitudinal samples from three representative healthy donors (black lines) and
three representative HIV-infected individuals (red lines). The HIV-infected individuals progressed to AIDS (CD4 count <200) within the depicted time
range.
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commensal bacteria, antibody responses were now analysed in
patients with IBD who are known to suffer from severe enter-
opathy, microbial translocation and a dysregulated microbiota.3
Elevated antibody responses to certain bacterial antigens (LPS,
flagellin) have been described before for IBD, mainly in the
context of CD.42e46 However, the majority of these studies only
Figure 5 Antibody responses to commensal microflora during chronic HIV-1 infection measured by live bacterial FACS analysis. Immunoglobulin A
(IgA), IgG and IgM responses to commensal gut bacteria (A), C albicans (B) and commensal skin bacteria (C). The median of multiple time points is
shown for each donor. p Values (*p<0.05; **p<0.01; ***p<0.001) were determined by two-sided Student t test. Statistical details are listed in
supplementary table 1.
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focused on certain bacterial products or bacterial lysates and we
wished to analyse the antibody response to whole intact gut
bacteria. This analysis should reveal whether (more severe)
enteropathy in comparison with HIV-1 may impact on the
antibody response to gut commensal bacteria.
Twenty-nine patients with IBD with different disease
phenotypes (active or mild CD, active or mild UC) and 19
age-matched healthy donors were analysed. The characteristics
of the study cohort are listed in table 2.
IgA, IgG and IgM responses to a human primary E coli isolate,
E coli Nissle, primary E faecalis, B fragilis, S epidermidis, K pneu-
moniae, B thetaiotaomicron, P acnes and C albicans were analysed.
IgA responses to E faecalis, IgG responses to K pneumoniae and B
thetaiotaomicron as well as IgA responses to C albicans were
Figure 6 Antibody responses to
commensal microflora in patients with
inflammatory bowel disease (IBD)
measured by live bacterial FACS
analysis. Immunoglobulin A (IgA), IgG
and IgM responses to commensal gut
bacteria (A), C albicans (B) and
commensal skin bacteria (C). One time
point per donor was analysed and is
depicted. p Values (*p<0.05) were
determined by two-sided Student t test.
Statistical details are listed in
supplementary table 1. CD, Crohn’s
disease; UC, ulcerative colitis.
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elevated in patients with IBD (figure 6). There was also a clear
trend for elevated E faecalis-specific IgG responses but no
differences for IgM titres. Antibody responses to E coli, B fragilis,
S epidermidis and P acnes were not statistically significant
between patients with IBD and healthy donors or when IBD
disease phenotypes were analysed separately. Elevated systemic
antibody titres specific for E faecalis, K pneumoniae, B thetaio-
taomicron and C albicans indicate that enteropathy is commonly
associated with increased antimicrobiota priming and suggests
that the inability to detect such priming in HIV-associated
enteropathy may be associated with poor ability to mount new
T cell-dependent antibody responses in patients with HIV or
lower levels of exposure to gut microbiota compared to patients
with IBD.
Low affinity antibodies against gut commensal bacteria are
comparable between patients with HIV and healthy controls
As the live bacterial FACS technology assay is mainly able to
detect high affinity bacterial antibodies we complemented our
analysis with ELISAs which also quantify low affinity anti-
bodies. We therefore compared two ELISA approaches with
respect to their specificity of detecting bacteria-specific antibody
responses, using either bacterial lysates or intact bacteria for
coating of ELISA plates. Based on the absence of systemic
antibody responses specific for the soil bacterium B japonicum
when assayed by live bacterial FACS (figure 2B), we used lysates
of B japonicum or whole B japonicum along with comparable
preparations of E coli in ELISAs to evaluate the specificity of the
respective coating procedures. Serum IgG antibodies of healthy
donors exhibited variable degrees of binding to both lysates of
B japonicum and whole bacteria (supplementary figure 3), indi-
cating that both coating procedures resulted in considerable
cross-reactivity, most probably due to exposure of conserved
bacterial proteins in the ELISA. As coating of whole bacteria
seems more comparable with live bacterial FACS analysis, we
used this procedure for the quantification of systemic antibody
responses to K pneumoniae, E faecalis and E coli in patients with
HIV, patients with IBD and the respective healthy control
groups. Optical density values from these ELISA measurements
were related to a standard plasma included in every assay to
determine an arbitrary titre for every sample (supplementary
figure 1B). Consistent with the results obtained with live
bacterial FACS analysis, systemic IgG titres specific for K pneu-
moniae and E faecalis were significantly increased in patients
with IBD. In contrast, no significant differences were observed
between patients with HIV and healthy controls for all three
tested bacteria (figure 7), further supporting the notion that
HIV-associated hypergammaglobulinaemia is not driven by
specificities for commensal gut bacteria.
Plasma levels of sCD14, but not of LPS and EndoCabIgM, are
altered during chronic HIV-1 infection
Since antibody responses to commensal bacteria do not seem to
reflect enteropathy and microbial translocation in patients with
HIV, other parameters associated with microbial translocation
were analysed to assess the level of enteropathy in the different
study groups. Plasma levels of sCD14, LPS and EndoCabIgM
have recently been introduced as markers of microbial trans-
location during HIV-1 infection.5 16 Plasma levels of sCD14
were analysed in the HIV-infected individuals with or without
diarrhoea, healthy donors and patients with IBD (figure 8A). In
agreement with previous reports, sCD14 was significantly
elevated in HIV-infected individuals. No differences were
observed between individuals with or without diarrhoea. In line
with a previous report, sCD14 was not elevated in patients with
IBD.47
The plasma samples with the highest levels of sCD14 were
subsequently analysed for LPS content (figure 8B). Neither
patients with HIV nor those with IBD showed markedly
increased levels of LPS. Levels of LPS were minimally increased
in patients with HIV, but the measured concentrations
(20e40 pg/ml) were much below the previously published
reports of >100e200 pg/ml.16 Endotoxaemia has also been
described in IBD, especially in the context of CD, but is also
reported to be very transient.34 42 47 48
EndoCabIgM were analysed in HIV-infected individuals with
or without diarrhoea as well as patients with IBD and healthy
donors (figure 8C). Only the HIV-infected individuals with
diarrhoea showed significantly higher levels of EndoCabIgM,
but only when compared with the HIV-infected individuals
without diarrhoea. No significant differences in EndoCabIgM
were found between the other study groups.
Figure 7 Antibody responses to gut
commensal bacteria measured by
ELISA. Immunoglobulin G (IgG)
responses to three gut commensal
bacteria were measured in patients
with HIV and those with inflammatory
bowel disease (IBD) and the respective
matched healthy control groups by
ELISA. For patients with HIV and those
with IBD one time point per donor was
analysed. p Values (*p<0.05) were
determined by two-sided Student t test.
CD, Crohn’s disease; UC, ulcerative
colitis.
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In summary, despite marked upregulation of sCD14, other
markers of microbial translocation were not substantially
dysregulated in our study group of HIV-infected individuals.
Maintenance of other antibody responses during chronic HIV-1
infection
As so far the majority of commensal antibody responses studied
here were not altered during chronic HIV-1 infection, other
antibody responses were now evaluated in light of the reported
HIV-associated B cell dysfunction. Antibody responses to novel
antigens and booster vaccines such as tetanus toxoid have
frequently been described to be impaired during chronic HIV-1
infection.22 24 49 50 However, coherent information on antibody
responses to persistent antigens (commensal bacteria, CMV) and
vaccine antigens (polio), which were acquired before HIV-1
infection, is missing.
Polio vaccination is generally only performed during child-
hood, and re-exposure occurs only very rarely. This presumes
that the polio-specific antibody response was acquired before
HIV infection and was not re-boosted afterwards. Seropositivity
(IgG) between the HIV-infected individuals and healthy donors
studied here was nearly equal (47% vs 41%). Among the sero-
positive individuals, the levels of polio IgG did not differ
significantly between the study groups (figure 9A). Patients
with HIV therefore successfully maintain specific serum anti-
body responses to viral vaccination antigens given before HIV
infection.
As described previously, CMV seropositivity (IgG) was higher
in the HIV-infected study group (78% vs 28%) (figure 9B). When
CMV-specific IgG titres were quantified longitudinally, the
magnitude of the response did not change with disease
progression (no correlation with CD4 counts or significant
decrease/increase over time, data not shown). CMV IgG levels
were equally high or even higher in the HIV-infected individuals
compared with the healthy donors. Overt CMV reactivation
was unlikely because CMV IgM responses remained below the
detection limit in all samples (data not shown). This is consis-
tent with previous reports about increased or unchanged levels
of CMV-specific antibodies during HIV-1 infection.51 52
Tetanus toxoid is an antigen which has generally been
encountered before HIV-1 infection, but revaccination is
required to maintain titres. The vaccination history of our study
individuals was not known in detail. However, as boosting
regimens with tetanus toxoid do not differ between healthy
controls and HIV-infected patients, we assumed that the
revaccination frequency would be similar in both study
groups. Interestingly, in line with previous reports, IgG
responses to tetanus toxoid were significantly lower in
Figure 8 Markers of microbial translocation during chronic HIV-1 infection compared with healthy donors and patients with inflammatory bowel
disease (IBD). Plasma or serum samples were analysed for (A) soluble CD14 (sCD14), (B) lipopolysaccharide (LPS) or (C) endotoxin core
immunoglobulin M antibodies (EndoCabIgM). p Values (*p<0.05; ***p<0.001) were determined by two-sided Student t test.
Figure 9 Maintenance of other
antibody responses during chronic
HIV-1 infection. Immunoglobulin G (IgG)
responses to polio (A), cytomegalovirus
(CMV) (B) and tetanus toxoid (C) in HIV-
infected individuals compared with
healthy donors. The dashed line
indicates the detection limit of the
assay. Samples below the detection
limit are considered as seronegative.
(D) IgG titres of HIV-infected individuals
with specificity for the gp120 surface
protein of the HIV-1 strain JR-FL.
p Values (***p<0.001) were
determined by two-sided Student t test.
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HIV-1-infected individuals compared with healthy donors
(figure 9C),23 50 indicative of failure to respond effectively to
boosting post-infection.
Finally, to assess the antibody response to a persistent antigen
which is acquired concomitantly with HIV-1, the IgG antibody
response to the HIV-1 envelope protein gp120 was analysed
longitudinally. All tested HIV-infected individuals had an IgG
response against the heterologous HIV JR-FL gp120 (figure 9D).
No correlation between gp120 binding titres and markers of
disease progression (CD4 counts and plasma viral load) was
observed (data not shown). This is in line with a recent report
showing that HIV-1 envelope-specific antibody responses are
maintained even in advanced stages of the disease.53
In summary, the maintenance of antibody responses acquired
before HIV-1 and/or to persistent antigens does not seem to be
severely impaired during chronic infection. However, IgG
responses to non-persistent tetanus toxoid antigen, which
require revaccinations and CD4 Tcell help also in healthy donors
to be maintained, were lower during chronic HIV-1 infection,
suggesting that the maintenance of antibody responses, also in
situations with low CD4 T cell counts, is dependent on the
nature (persistence, immunogenicity) of the antigen.
DISCUSSION
The present study shows that systemic antibody responses to
gut commensal bacteria are abundantly available in humans and
the magnitude of responses to given bacteria may differ up to
1000-fold between individuals, but remains remarkably stable
over years. Enteropathy associated with HIV has no or only very
little effect on these systemic antibody responses when quan-
tified per unit volume of the plasma in the concomitant presence
of HIV-associated hypergammaglobulinaemia. Thus, patients
with HIV, despite severe B cell disturbances, manage to maintain
normal levels of antibody responses to gut commensal bacteria,
even at very late stages of the infection.
The evident priming of systemic antibody responses to
intestinal bacteria in humans at first appears to diverge from the
notion of tight compartmentalisation between intestinal and
systemic antibody responses as established in specific pathogen-
free mice where systemic IgG responses to commensal bacteria
are undetectable.28 54 55 However, anticommensal microbe IgG
responses are known to be induced and protective in the case of
mice with deficiencies in innate immunity.28 Living outside of
the laboratory environment with common bouts of enteropathy
throughout childhood and into adult life almost certainly
underlies the observed human systemic IgG responses to gut
commensal bacteria. Evidence of systemic antibody responses to
commensal bacteria has been provided before,30 34 56 but was
never analysed with such specificity and depth in a large cohort
of longitudinal samples as presented here.
As systemic priming to commensal bacteria is clearly ubiqui-
tous in humans, we investigated how these responses might be
affected by enteropathy. Chronic enteropathy in humans has
frequently been described in the context of IBD, but is also
known for HIV-1 infection.5 10 Several studies associate HIV
enteropathy with systemic translocation of microbial products
such as LPS,16 bacterial butyrate15 and bacterial DNA.57 Systemic
translocation of LPS is suggested to drive chronic immune acti-
vation, which is a hallmark of HIV-1 infection and progression
towards AIDS.16 Further, HIV infection is also associated with
severe B cell disturbances22 as memory B cell responses are
reported to be impaired, especially in the context of vaccina-
tion.23 24 49 50 Conversely, B cell hyperactivity, observed in serum
as well as in the intestinal tissue, and hypergammaglobulinaemia
of unknown antigen specificity are observed without clear
evidence for the underlying mechanisms.23 25 58Although a role
for an antigen-dependent mechanism underlying B cell hyper-
activation could so far not be completely excluded, the vast
majority of published reports indicate that polyclonal stimula-
tion independent of B cell receptor (BCR) specificity may drive B
cell hyperactivation and hypergammaglobulinaemia.22 23 59
Alternatively, viral molecules and Toll-like receptor (TLR) ligands
have been described to trigger (antigen-independent) polyclonal B
cell activation. The HIV-1 envelope protein gp120 can interact
with the complement receptor CD21 and the C-type lectin
receptor DC-SIGN, which are both expressed on B cells.60 61
These interactions have been associated with increased sponta-
neous Ig secretion and polyclonal B cell activation.60 62 63 Similar
to T cells, an indirect activatory effect via HIV-infected macro-
phages has been ascribed to Nef, but this contradicts a report of
Nef-induced class switch inhibition.22 64
A role for TLR stimulation of B cells has mainly been
discussed in the context of serological maintenance of antibody
titres,65 but may well be applicable to hyperactivation and
hypergammaglobulinaemia: memory B cells respond to TLR9,
which recognises CpG DNA, and start to proliferate and secrete
Ig independently of BCR triggering.65 66 Naive B cells, however,
are reported only to upregulate TLR9 upon activation by BCR
triggering,65 66 which may be relevant in the context of
a proposed mechanism stating that polyclonal activation of
naive B cells mainly contributes to hypergammaglobulinaemia.23
It has indeed been shown that B cells from HIV-1-infected
donors are responsive to stimulation by CpG DNA.58 Increased
levels of LPS, however, may be excluded as a direct contributor
to TLR-mediated polyclonal B cell activation since B cells do not
express TLR4 along with the majority of other TLRs.66 67
Furthermore, cytokines and involvement of T cell help have
been described in the context of HIV-associated polyclonal B cell
activation: T cell help provided to B cells via CD40/CD40L
interaction is often discussed as a contributor to B cell activa-
tion, also in the absence of BCR triggering. It has been reported
that during HIV-1 infection the frequency of T cells expressing
CD40L and thus being able to provide co-stimulation to B cells
is increased.68 Similar to TLR9 stimulation, T cell help provided
by activated CD4 T cells was shown to induce proliferation
and Ig secretion by memory B cells.65 69 Thus, in such a scenario
the observed hypergammaglobulinaemia in vivo would be
a secondary effect of the high level of activation of CD4 Tcells.
The data presented in this study are consistent with an
antigen-independent mechanism underlying HIV-associated B
cell hyperactivation and hypergammaglobulinaemiadat least
with respect to a selection of gut microbial antigens. Our data
show that HIV-infected individuals, even in late stages of the
disease, maintain normal levels of low and high affinity antibody
responses towards gut commensal bacteria per unit volume of
plasma. As observed for healthy donors, these levels remain
remarkably stable over the whole course of infection and do
not correlate with any parameters of disease progression. Even
during episodes of diarrhoea, which are associated with
enhanced intestinal permeability during HIV-1 infection,13 no
impact on systemic antibody responses was observed.
These data indicate that HIV enteropathy is not reflected in
changes of systemic antibody responses specific for gut
commensal bacteriadat least for the panel of gut bacteria which
were used for analysis. Furthermore, our data indicate that
HIV-associated B cell dysfunction does not completely obliterate
the ability to produce and maintain systemic antibody responses.
Indeed, increased antibody titres were observed for both CMV
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and Candida and, similar to gut commensal bacteria, polio-
specific antibody levels were comparable between HIV-infected
individuals and healthy controls.
As HIV-associated enteropathy and B cell disturbances do not
alter the antibody responses to gut commensal bacteria, we
subsequently studied antibody responses in patients with IBD.
IBD is associated with severe enteropathy, but is not clearly
related to any major systemic immunodeficiency or B cell
dysfunction. In patients with IBD we indeed observed elevated
systemic antibody responses to a number of gut commensal
bacteria, probably driven by increased exposure to intestinal
commensal antigens in IBD. Although the underlying cause of
UC or CD remains unclear, in the absence of overt T or B cell
immunodeficiency, enteropathy is clearly associated with
increased antimicrobiota antibody titres. This suggests that
either the immunodeficiency or the nature of the enteropathy
prevents excessive priming against the intestinal microbiota in
HIV-infected individuals. It should be noted in this context that
gut bacterial surface-specific antibody responses, at least in mice,
seem to depend on CD4 T cell help,28 70 and intestinal CD4 T
cells are massively depleted in HIV-1 infection.7 8 Owing to lack
of faecal material or intestinal histology from the Swiss HIV
cohort, we cannot exclude specific effects of HIV infection on
local mucosal antibody responses as has been observed in the
severe intestinal lesions in IBD.71
To quantify the extent of enteropathy-associated microbial
translocation, we measured previously reported markers of
bacterial translocation in both patients with HIVand those with
IBD. Several studies have reported increased levels of LPS and
sCD14 during chronic HIV-1 infection which have been attrib-
uted to HIVenteropathy and microbial translocation.5 16 72 73 In
addition, decreased levels of EndoCabIgM were associated
with chronic LPS exposure and B cell dysfunction during chronic
HIV-1 infection.16 74
Within our cohort, sCD14 was significantly elevated in the
HIV-infected individuals but this was not associated with
similar increases in plasma levels of LPS or alterations in Endo-
CabIgM levels. Two other studies in African cohorts and one
study in a European cohort also failed to detect elevated levels of
LPS in the plasma 32 75 76 or altered EndoCabIgM levels.76 It
could be speculated that regional differences or blood collection
and storage methods may account for the unchanged levels of
LPS and EndoCabIgM in European and African study groups.
However, a new study in South African HIV-infected individuals
also reported increased levels of plasma LPS compared with
healthy controls.77
Recently, elevated levels of sCD14 during chronic HIV-1
infection have been attributed to increased LPS exposure.16 74
However, it has previously also been shown that treatment of
monocytes with the HIV-1 envelope protein gp12078 or other
stimuli79 induces release of sCD14. These and our findings may
implicate that increased levels of sCD14 during chronic HIV-1
infection may rather be a general marker of aberrant activation
of monocytes and may not necessarily be a sole consequence
of increased LPS exposure. This is also supported by the fact
that sCD14 is generally not elevated in patients with IBD47
despite some reports indicating transiently increased levels of
LPS.34 42 47 48
Therefore, the absence of increased antimicrobiota IgA and
IgG in HIV is likely to be due to mild or transient intestinal
commensal translocation, as determined by the absence of
strong serum markers of bacterial translocation, possibly also
involving the ability of liver sinusoidal cells and Kupffer cells to
effectively clear IgA-coated bacteria from the circulation80 81 and
the intrinsic immunodeficiency in HIV failing to induce new
antigen-specific antibody responses. This is in contrast to indi-
viduals with IBD, showing elevated systemic antibody titres to
several gut commensal bacteria.
In conclusion, our data show that HIV-associated enteropathy
is not associated with increased systemic antibody responses to
a number of commensal gut bacteria, including bacterial species
to which systemic antibody responses were clearly elevated in
patients with IBD, and further that antigen-specific effects of
the translocating microbiota are unlikely to contribute to
hypergammaglobulinaemia.
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